{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Participants who have a Clinical Benefit Rate/CBR"},{"measurements":[{"groupId":"OG000","value":"7"}],"title":"Participants without a Clinical Benefit Rate/CBR"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"The CBR is defined as the proportion of patients CR, PR or SD at 18 weeks based on RECIST criteria.","groups":[{"description":"pevonedistat: Pevonedistat will be administered as an IV infusion at a dose of 50 mg/m2 days 1, 3, and 5 of a 21-day cycle.Treatment will be administered as an outpatient.","id":"OG000","title":"Pevonedistat"},{"description":"pevonedistat: Pevonedistat will be administered as an IV infusion at a dose of 50 mg/m2 days 1, 3, and 5 of a 21-day cycle.Treatment will be administered as an outpatient.\n\nPemetrexed and cisplatin: Pemetrexed, 500 mg/m2 and cisplatin, 75 mg/m2, will be given at fixed doses on day 1 of each cycle.","id":"OG001","title":"Pevonedistat in Combination With Pemetrexed and Cisplatin"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"No participants accrued to pevonedistat in combination with pemetrexed and cisplatin cohort","reportingStatus":"POSTED","timeFrame":"at 18 weeks post initiation of treatment","title":"Number of Patients Who Have a Clinical Benefit Rate (CBR) (Cohort 1)","type":"PRIMARY","unitOfMeasure":"Participants"}